Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Acquire MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Second Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.